Accelerated Biological Aging, Neurodegenerative Disease, and Mortality in Cardiovascular Disease Patients: Mediation and Modification Analysis.
Accelerated Biological Aging, Neurodegenerative Disease, and Mortality in Cardiovascular Disease Patients: Mediation and Modification Analysis.
Where did the research take place?
The study site has not been established. Author addresses may differ from where the research occurred.
Beijing, CN · Author affiliation
National Stroke Administration Office, Xuanwu Hospital Capital Medical University, Beijing, China.Location evidence
A plain-language reading has not been prepared for this paper yet.
Original abstract
AIMS: Cardiovascular disease (CVD) patients exhibit increased neurodegenerative diseases and mortality risks, implying a shared heart-brain aging pathway. As a composite biological aging predictor, the association of Phenotypic age (PhenoAge) with mortality and the mediating role of brain health remain unclear in CVD patients. METHODS: In 4104 CVD patients (57.3% male, mean age 67.3 years) from the National Health and Nutrition Examination Survey (median follow-up of 7.2 years), weighted regression models examined associations of PhenoAge and its acceleration with Alzheimer's disease (AD), Parkinson's disease (PD), and mortality. Mediation effects of the association between PhenoAge and mortality explained by AD and PD were quantified. RESULTS: The mean PhenoAge was 69.9 years, and AD and PD prevalences were 7.6% and 1.8%. Each 5-year increment of PhenoAge acceleration independently increased risks of AD (OR = 1.24; 95% CI:1.13,1.36), PD (OR = 1.22; 95% CI:1.02,1.46), and all-cause mortality (HR = 1.30; 95% CI:1.24,1.36). AD and PD mediated 20.46%-33.18% of the association between PhenoAge and mortality. Early-onset CVD amplified biological aging-related mortality risk, while a healthier lifestyle attenuated the CVD mortality risk (Pinteraction < 0.05). CONCLUSION: Accelerated biological aging was associated with adverse brain health outcomes and mortality in CVD patients, with AD and PD as significant mediators. PhenoAge assessment may identify high-risk individuals for personalized heart-brain aging prevention.